Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Functional precision oncology using patient-derived assays: bridging genotype and phenotype.

Nature reviews. Clinical oncology - 1 May 2023

van Renterghem Allard W J, van de Haar Joris, Voest Emile E

Abstract excerpt

Genomics-based precision medicine has revolutionized oncology but also has inherent limitations. Functional precision oncology is emerging as a complementary approach that aims to bridge the gap between genotype and phenotype by modelling individual tumours in vitro. These patient-derived ex vivo models largely preserve several tumour characteristics that are not captured by genomics approaches and enable the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to 3D Printing in Biomedical Research
Share to Cancer Cells and Metastasis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cancer Genomics and Diagnostics

Share to Genotype

Share to Medical Oncology

Share to Neoplasms

Share to Phenotype

Share to Precision Medicine

Source

Identifiers

PMID: 36914745
DOI: 10.1038/s41571-023-00745-2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Functional precision oncology using patient-derived assays: bridging genotype and phenotype.PMID 36914745Read ↗

Precision Oncology at a Crossroads: How Organoid Platforms Are Reshaping the FieldSemantic proximity Read ↗

Molecular Oncodiagnostics in Precision Oncology: Integrating Tumor Transcriptomics, Patient Pharmacogenetics, and Ex Vivo Chemoresistance Testing to Improve Individual Chemotherapy ResponseSemantic proximity Read ↗

Systematic functional drug testing in patient-derived models reveals ex vivo sensitivities associated with clinical outcome in rare solid tumorsSemantic proximity Read ↗

Functional Drug Screening in the Era of Precision MedicineSemantic proximity Read ↗

Functional precision oncology: Testing tumors with drugs to identify vulnerabilities and novel combinations.Semantic proximity Read ↗

In vitro patient-derived 3D mesothelioma tumor organoids facilitate patient-centric therapeutic screeningSemantic proximity Read ↗

Will Organoids Fill the Gap towards Functional Precision Medicine?Semantic proximity Read ↗

Subclonal response heterogeneity to define cancer organoid therapeutic sensitivitySemantic proximity Read ↗

Phenotype-driven precision oncology as a guide for clinical decisions one patient at a time.Semantic proximity Read ↗

Patient-derived organoids across cancers reveal conserved tumor heterogeneity and actionable therapeutic vulnerabilities.Semantic proximity Read ↗

A microfluidic platform for functional assays on tumour biopsy-derived spheroids for precision medicineSemantic proximity Read ↗

Implementing cell-free DNA of pancreatic cancer patient–derived organoids for personalized oncologySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.